MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study.

ABSTRACT:

Introduction

This is the first North American clinical evidence for MV140, a novel bacterial sublingual vaccine, developed for prevention of recurrent urinary tract infection (UTI) in women.

Methods

Female subjects with ≥3 documented UTIs/year underwent three-month vaccination treatment, nine-month efficacy period, and optional three-month followup (total 15 months). Primary outcome was no clinically diagnosed UTI following vaccination (UTI-free rate). Secondary outcomes included absolute, mean, and median overall reduction in UTI compared to pre-vaccination, quality of life, global response assessment, patient satisfaction, microbiology, and safety.

Results

Sixty-seven subjects (mean age 56 years, range 18-80) were enrolled; 64 completed the vaccination period and at

SUBMITTER: Nickel JC 

PROVIDER: S-EPMC10841562 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature